中國鐵建(01186.HK)下屬聯合體中標杭州富春灣合作方採購項目 總投資204.14億元
格隆匯5月18日丨中國鐵建(01186.HK)發佈公告,近日,公司下屬中國鐵建投資集團有限公司等單位組成聯合體中標杭州富春灣新城春北片區開發項目合作方採購項目。項目總投資為204.14億元。項目開發週期為12年。
項目資本金佔總投資的30%。項目公司註冊資本金5億元,杭州富春灣新城建設投資集團有限公司與中國鐵建投資集團有限公司等單位組成的聯合體按照10%:90%的股權比例出資。除項目資本金以外的其餘資金由項目公司作為融資主體通過銀行貸款方式籌措。以上項目的投標已經公司第四屆董事會第三十八次會議審議批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.